<DOC>
	<DOC>NCT01712919</DOC>
	<brief_summary>The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.</brief_summary>
	<brief_title>Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Pathologically confirmed untreated NPC patients locoregionally advanced (T34 or N23 M0) 1865 years with MRI examinations ECOG â‰¤ 2 With written consent Without a second cancer Pregnancy With other severe diseases (blood,liver ,kidney or heart diseases) Could not be staged properly Without written consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Locoregionally advanced nasopharyngeal carcinoma</keyword>
	<keyword>cetuximab</keyword>
	<keyword>chemoradiation</keyword>
</DOC>